Cyclooxygenase inhibition improves endothelial vasomotor dysfunction of visceral adipose arterioles in human obesity

Obesity

Volumn 22, Issue 2, 2014, Pages 349-355

  Farb, Melissa G ^a   Tiwari, Stephanie ^a   Karki, Shakun ^a   Ngo, Doan T M ^a   Carmine, Brian ^a   Hess, Donald T ^a   Zuriaga, Maria A ^a   Walsh, Kenneth ^a   Fetterman, Jessica L ^a   Hamburg, Naomi M ^a   Vita, Joseph A ^a   Apovian, Caroline M ^a   Gokce, Noyan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTERIOLES; BODY MASS INDEX; CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTRA-ABDOMINAL FAT; MALE; MICROSCOPY, VIDEO; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SUBCUTANEOUS FAT, ABDOMINAL; TISSUE CULTURE TECHNIQUES; VASOCONSTRICTION; VASOMOTOR SYSTEM;

EID: 84895905811     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20505     Document Type: Article

References (40)

1. Berrington de GA, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363: 2211-2219.
2. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
3. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39-48.
4. Parikh NI, Keyes MJ, Larson MG, et al. Visceral and subcutaneous adiposity and brachial artery vasodilator function. Obesity (Silver Spring) 2009; 17: 2054-2059.
5. Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007; 116: 1234-1241.
6. Farb MG, Ganley-Leal L, Mott M, et al. Arteriolar function in visceral adipose tissue is impaired in human obesity. Arterioscler Thromb Vasc Biol 2012; 32: 467-473.
7. Virdis A, Santini F, Colucci R, et al. Vascular generation of tumor necrosis factor-alpha reduces nitric oxide availability in small arteries from visceral fat of obese patients. J Am Coll Cardiol 2011; 58: 238-247.
8. Greenstein AS, Khavandi K, Withers SB, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009; 119: 1661-1670.
9. Campia U, Choucair WK, Bryant MB, et al. Role of cyclooxygenase products in the regulation of vascular tone and in the endothelial vasodilator function of normal, hypertensive, and hypercholesterolemic humans. Am J Cardiol 2002; 89: 286-290.
10. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-409.
11. Pratico D, Tillmann C, Zhang ZB, et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 2001; 98: 3358-3363.
12. Taddei S, Virdis A, Ghiadoni L, et al. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997;29(1, Part 2): 274-279.
13. Tesfamariam B, Brown ML, Deykin D, et al. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990; 85: 929-932.
14. Traupe T, Lang M, Goettsch W, et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 2002; 20: 2239-2245.
15. Widlansky ME, Price DT, Gokce N, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003; 42: 310-315.
16. Xiang L, Dearman J, Abram SR, et al. Insulin resistance and impaired functional vasodilation in obese Zucker rats. Am J Physiol Heart Circ Physiol 2008; 294: H1658-H1666.
17. Zhou Y, Varadharaj S, Zhao X, et al. Acetylcholine causes endothelium-dependent contraction of mouse arteries. Am J Physiol Heart Circ Physiol 2005; 289: H1027-H1032.
18. Tabit CE, Shenouda SM, Holbrook M, et al. Protein kinase C-beta contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 2013; 127: 86-95.
19. Rouzer CA, Marnett LJ,. Cyclooxygenases: structural and functional insights. J Lipid Res 2009; 50 (Suppl): S29-S34.
20. Ricciotti E, FitzGerald GA,. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 986-1000.
21. Helmersson J, Vessby B, Larsson A, et al. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004; 109: 1729-1734.
22. Taddei S, Virdis A, Mattei P, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29: 736-743.
23. Kukreja RC, Kontos HA, Hess ML, et al. PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. Circ Res 1986; 59: 612-619.
24. Tang EH, Vanhoutte PM,. Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther 2009; 122: 140-149.
25. Tesfamariam B, Cohen RA,. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol 1992; 262, (6 Part 2): H1915-H1919.
26. Annuk M, Fellstrom B, Lind L,. Cyclooxygenase inhibition improves endothelium-dependent vasodilatation in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17: 2159-2163.
27. Edlund A, Berglund B, van DD, et al. Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. Circulation 1985; 71: 1113-1120.
28. Friedman PL, Brown EJ Jr, Gunther S, et al. Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease. N Engl J Med 1981; 305: 1171-1175.
29. Pacold I, Hwang MH, Lawless CE, et al. Effects of indomethacin on coronary hemodynamics, myocardial metabolism and anginal threshold in coronary artery disease. Am J Cardiol 1986; 57: 912-915.
30. Bagi Z, Erdei N, Toth A, et al. Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol 2005; 25: 1610-1616.
31. Liu B, Luo W, Zhang Y, et al. Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries. Exp Physiol 2012; 97: 277-289.
32. Tang EH, Ku DD, Tipoe GL, et al. Endothelium-dependent contractions occur in the aorta of wild-type and COX2-/- knockout but not COX1-/- knockout mice. J Cardiovasc Pharmacol 2005; 46: 761-765.
33. Zou MH,. Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Other Lipid Mediat 2007; 82: 119-127.
34. He C, Choi HC, Xie Z,. Enhanced tyrosine nitration of prostacyclin synthase is associated with increased inflammation in atherosclerotic carotid arteries from type 2 diabetic patients. Am J Pathol 2010; 176: 2542-2549.
35. Williams SP, Dorn GW, Rapoport RM,. Prostaglandin I2 mediates contraction and relaxation of vascular smooth muscle. Am J Physiol 1994; 267(2, Part 2): H796-H803.
36. Belhassen L, Pelle G, Dubois-Rande JL, et al. Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41: 1198-1204.
37. Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 334-342.
38. Zuccollo A, Shi C, Mastroianni R, et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation. 2005; 112: 3001-3008.
39. Kanter JE, Kramer F, Barnhart S, et al. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci USA 2012; 109: E715-E724.
40. Martinez-Revelles S, Avendano MS, Garcia-Redondo AB, et al. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal 2013; 18: 51-65.